Zai Lab (ZLAB) Projected to Post Quarterly Earnings on Thursday

Zai Lab (NASDAQ:ZLAB - Get Free Report) will likely be announcing its earnings results before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.65) per share and revenue of $108.53 million for the quarter. Investors interested in registering for the company's conference call can do so using this link.

Zai Lab Price Performance

ZLAB stock traded up $2.79 during midday trading on Friday, reaching $33.78. 2,093,498 shares of the company's stock traded hands, compared to its average volume of 729,782. The company has a market capitalization of $3.70 billion, a P/E ratio of -12.19 and a beta of 1.02. Zai Lab has a fifty-two week low of $13.48 and a fifty-two week high of $36.60. The business has a 50-day moving average price of $26.90 and a two-hundred day moving average price of $25.22.

Insider Buying and Selling at Zai Lab

In other news, insider Rafael Amado sold 7,583 shares of the business's stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total transaction of $199,281.24. Following the transaction, the insider now directly owns 33,834 shares of the company's stock, valued at approximately $889,157.52. The trade was a 18.31 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 13.88% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald raised shares of Zai Lab to a "strong-buy" rating in a research report on Wednesday, February 5th.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.